Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

German hospitals blast quality institute over stem cell therapy move:

This article was originally published in Clinica

Executive Summary

The German healthcare HTA body IQWiG (healthcare quality and economy institute), the executive arm of the G-BA reimbursement decision-making body, has come under fire from the national hospitals federation (DKG) over a negative recommendation on stem cell therapy in acute leukaemia cases. DKG president Dr Rudolf Kosters disagreed with the recommendation, delivered in a report in June 4, saying that IQWiG's methodology was not suited to this type of decision-making, that the G-BA should not base action on the recommendation pending further consultation, and that it is counter to established scientific knowledge. The report would doubtless provoke major concerns among seriously ill patients, he said, adding that transplant centres need to be able to implement the highest standards of care.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048945

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel